The burden of asthma is immense, with more than 300 million individuals currently suffering from asthma worldwide, about a tenth of those living in India. The prevalence of asthma has been estimated to range 3-38% in children and 2-12% in adults, being the commonest chronic disorder among children. Indian asthmatics have a high frequency of reported exacerbations (67%), leading to substantial functional and emotional limitations. This depicts poor control of asthma and reflects the inadequate treatment of such patients.
This article emphasizes on a new agent which tends to treat asthma exacerbations. In patients with moderate to severe asthma, who are on treatment with long-acting beta agonist and medium to high doses of inhaled glucocorticoids, treatment with tezepelumab resulted in lower rate of clinically significant asthma exacerbations as compared to placebo . These results…
